(1) How to enhance supply-chain security. 
(2) Consumer education on counterfeiting 
issues. 
(3) Employing technology designed to frustrate 
organized and sophisticated criminals intent on com-
promising the world’s drug supply. 
(4) How industry could assist law enforcement 
by analyzing suspected counterfeit drugs to deter-
mine authenticity. 
(5) How industry can collaborate on issues re-
lated to pharmaceutical counterfeiting without re-
vealing trade secrets or other confidential informa-
tion. 
(d) REPORT.—Not later than 2 years after the date 
of the enactment of this Act, the working group shall sub-
mit a report to the Congress on the results of the study 
conducted under this section, including recommendations 
on measures to reduce or eliminate problems associated 
with pharmaceutical counterfeiting. 
SEC. 6. STUDY ON UNUSED CONTROLLED SUBSTANCES. 
(a) STUDY.—The Secretary of Health and Human 
Services (in this section referred to as the ‘‘Secretary’’), 
acting through the Commissioner of Food and Drugs, 
shall conduct a study to determine the best methods to
ensure that unused controlled substances are not diverted 
for unlawful use. 
(b) CONSULTATION.—In conducting the study re-
quired by this section, the Secretary shall consult with the 
Administrator of the Drug Enforcement Administration, 
appropriate law enforcement representatives, the Adminis-
trator of the Environmental Protection Agency, States 
and municipalities (including State boards of pharmacy), 
and representatives of the pharmaceutical industry. 
(c) REPORT.—Not later than 2 years after the date 
of the enactment of this Act, the Secretary shall submit 
a report to the Congress on the results of the study con-
ducted under this section. 
SEC. 7. BASELINE RESEARCH ON PRESCRIPTION DRUG 
ABUSE. 
(a) RESEARCH.—The Secretary of Health and 
Human Services shall conduct research on issues related 
to prescription drug abuse, including the following: 
(1) Enhancing existing public use surveys and 
other sources so as to provide appropriate baseline 
data and data on the natural history and context of 
prescription drug use in order to evaluate the extent 
and nature of potential problems and guide correc-
tive actions which reduce the problems without unin-
tentionally hindering patient access.
(2) The phenomenon of iatrogenic addiction, in-
cluding the actual incidence and prevalence of iatro-
genic addiction, the factors that modulate the risk of 
such addiction, and the extent to which concern 
about iatrogenic addiction impacts health care deliv-
ery. 
(3) Development of postapproval surveillance 
approaches that can detect and address potential 
risks of abuse and misuse, including risks in diverse 
patient populations that did not previously appear at 
risk for diversion or abuse, and in geographic re-
gions that have been relatively absent from risk. 
(4) Methods to better translate new ideas about 
terminology, diagnosis, and management of addic-
tion diseases into clinical practice at the primary 
care and specialist levels. 
(5) Reliable, useful assessment tools for addic-
tion in the clinical setting of initial and ongoing 
treatment of conditions requiring the use of con-
trolled substances. 
(6) Development of better methods of ensuring 
patient adherence to prescribed drug regimens. 
(7) Relative contributions of genetic, psycho-
social, environmental, and behavioral factors to ad-
diction to prescription opioids.
(b) REPORT.—Not later than 2 years after the date 
of the enactment of this Act, the Secretary of Health and 
Human Services shall submit to the Congress a report on 
the results of the research conducted under this section. 
SEC. 8. DATABASE FOR DRUG ABUSE MORTALITY REPORT-
ING. 
Section 505 of the Public Health Service Act (42 
U.S.C. 290aa–4) is amended— 
(1) in subparagraph (B) of subsection (c)(1), by 
striking ‘‘, as indicated in reports by coroners’’; and 
(2) by adding at the end the following: 
‘‘(e) With respect to the activities of the Adminis-
trator under subsections (a) and (c)(1)(B) relating to the 
collection of data on the number of deaths occurring as 
a result of substance abuse, the Administrator— 
‘‘(1) shall expand and intensify collection activi-
ties to maintain a comprehensive, national database 
on such deaths; and 
‘‘(2) shall require medical examiners, coroners, 
and other appropriate persons to report to the Ad-
ministrator for purposes of collecting data on such 
deaths.’’. 
Æ